Pharmaceuticals

Inovio Pharmaceuticals held its first-quarter 2026 earnings call on May 13 to discuss financial results for the period ended March 31 and provide updates on its DNA medicines platform.

13 Mwezi wa tano, 2026 Imeripotiwa na AI

A Japanese health panel has approved national health insurance coverage for Sumitomo Pharma's Amchepry, an iPS cell-derived treatment for Parkinson’s disease. The move makes it the world's first commercialized medical product from iPS cells.

Pharco Pharmaceuticals plans to invest around EGP 1.5bn next year, up from about EGP 1.15bn in 2025, to expand production capacity and strengthen its presence in domestic and export markets, Chairperson Sherine Helmy said. The company is prioritising improvements in product quality alongside expansion and diversification of production lines.

4 Mwezi wa tano, 2026 Imeripotiwa na AI

Nuvation Bio Inc. conducted its first quarter 2026 earnings call on May 4, 2026. The company reviewed financial results for the period ending March 31, 2026, and provided a business update. Executives including CEO David Hung participated in the discussion.

Sun Pharmaceutical Industries' shares surged more than 9% following the announcement of its $11.75 billion acquisition of US-based Organon & Co. The deal targets bolstering the Indian company's innovative medicines and positioning it strongly in biosimilars and women's health markets. Organon is recognized as a global leader in women's health.

22 Mwezi wa nne, 2026 Imeripotiwa na AI

Pharco Pharmaceuticals has inaugurated a specialized production line for eye drops at its Amreya City facility in Alexandria, with investments exceeding EGP 500m. The line has an annual capacity of 20 million packs, covering about 19% of Egypt's domestic demand. It supports efforts to localize drug manufacturing and reduce import reliance.